Sangamo BioSciences | SGMO - Bienes





Bienes Cambio Fecha
Alaunos Therapeutics USD 1.88M 1.08M 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Alterity Therapeutics Limited AUD 37.98M 15.78M 2025-12
Amgen USD 92.5B 1.92B 2026-03
Bayer EUR 107.94B 3.4B 2026-03
BioCryst Pharmaceuticals USD 465.05M 49.11M 2026-03
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Cipla INR 424.96B 23.32B 2026-03
Clal Biotechnology ILS 158.39M 24.3M 2023-12
Compugen USD 156.57M 58.73M 2025-12
CSL USD 37.9B 1.5B 2025-12
Gilead Sciences USD 56.28B 2.74B 2026-03
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Grifols EUR 23.15B 142.7M 2025-12
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
J&J USD 200.89B 1.68B 2026-03
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
Merck USD 128.68B 8.18B 2026-03
Novartis USD 118.53B 7.58B 2026-03
Omeros USD 200.57M 34.59M 2025-06
Pfizer USD 207.62B 542M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 128.02B 1.22B 2026-03
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
Tectonic Therapeutic USD 246.58M 14.46M 2026-03
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03